Syndax Announces Participation in September Investor Conferences

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [2] - The company has FDA-approved products in its pipeline, including Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr) [2] - Syndax is actively participating in upcoming investor conferences to engage with stakeholders [1][3] Company Overview - Syndax Pharmaceuticals is dedicated to advancing cancer care through its innovative therapies [2] - The company is conducting several clinical trials to maximize the potential of its product pipeline [2] Upcoming Events - Syndax's CEO and management team will participate in Citi's 2025 BioPharma Back to School Conference on September 2, 2025 [3] - The company will also present at H.C. Wainwright's 27th Annual Global Investment Conference on September 8, 2025 [3]